Athira Pharma (NASDAQ:ATHA) CEO Sells $17,791.68 in Stock

Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton sold 2,586 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $6.88, for a total transaction of $17,791.68. Following the transaction, the chief executive officer owned 40,828 shares in the company, valued at $280,896.64. The trade was a 5.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Athira Pharma Stock Down 5.5%

ATHA stock traded down $0.38 during trading on Monday, hitting $6.58. The company had a trading volume of 163,152 shares, compared to its average volume of 3,184,091. The firm has a 50-day moving average price of $5.03 and a 200-day moving average price of $4.27. Athira Pharma, Inc. has a 12 month low of $2.20 and a 12 month high of $8.36. The stock has a market cap of $25.93 million, a price-to-earnings ratio of -0.68 and a beta of 2.79.

Athira Pharma (NASDAQ:ATHA) last released its earnings results on Thursday, November 6th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($0.17) by ($1.51). Equities analysts expect that Athira Pharma, Inc. will post -2.35 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Athira Pharma stock. Focus Partners Wealth purchased a new position in Athira Pharma, Inc. (NASDAQ:ATHA) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,415 shares of the company’s stock, valued at approximately $35,000. Focus Partners Wealth owned approximately 0.21% of Athira Pharma at the end of the most recent reporting period. Institutional investors own 57.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Mizuho set a $4.00 target price on shares of Athira Pharma in a research report on Friday, September 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell” and an average target price of $4.00.

About Athira Pharma

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.